Management of medullary thyroid cancer

Area of Science:

• Oncology
• Molecular Genetics
• Clinical Pharmacology

Background:

• Medullary thyroid cancer (MTC) frequently harbors activating RET gene mutations, impacting prognosis.
• RET mutations, particularly M918T, are significant negative prognostic factors in MTC.
• RET and vascular endothelial growth factor receptors are key targets for MTC systemic therapies.

Purpose of the Study:

• To review recent clinical trial data on multikinase inhibitors for medullary thyroid cancer.
• To evaluate the efficacy and toxicity of agents like motesanib, vandetanib, sunitinib, sorafenib, and cabozantinib.
• To address patient selection and integration of systemic therapies with surgery and radiation.

Main Methods:

• Review of recent clinical trials data for multikinase inhibitors in MTC.
• Analysis of efficacy and toxicity profiles of specific agents.
• Discussion of patient selection criteria and treatment integration strategies.

Main Results:

• Approximately 55% of MTC tumors exhibit activating RET gene mutations.
• Multikinase inhibitors targeting RET and VEGFR show promise in MTC treatment.
• RET mutation status has not yet reliably predicted patient response to these inhibitors.

Conclusions:

• Systemic therapies, particularly multikinase inhibitors, represent a promising avenue for MTC treatment.
• Further research is needed to identify predictive biomarkers for patient response.
• Optimizing the selection of MTC patients and integrating new therapies with existing modalities are critical.